Abstract Background: While HPV vaccination and Pap screening have advanced cervical cancer (CCa) prevention, high-grade squamous intraepithelial lesions (HSIL) remain common, particularly among individuals with metabolic comorbidities such as diabetes and hypercholesterolemia. Statins, commonly used for lipid control, possess anti-inflammatory and antiproliferative properties that may offer protective effects against cervical dysplasia. We evaluated whether statin use is associated with reduced HSIL risk and explored whether effects vary by comorbidity and race. Patients and Methods: We retrospectively analyzed electronic health records and billing data from 2,378 non-Latina/e (nL) Black and nL-White patients diagnosed with LSIL or HSIL between 2014 and 2021 at a large academic medical center. Logistic regression assessed associations between statin use, comorbidity profiles (diabetes and hypercholesterolemia), race, and HSIL, adjusting for potential confounders. Interaction terms were tested to evaluate effect modification. Results: Statin users had significantly lower odds of HSIL than nonusers (adjusted OR=0.48, p0.0001), despite being older and more likely to have comorbidities. Predicted HSIL probabilities ranged from 4% to 20% in statin users versus 13% to 29% in nonusers. The lowest risk was observed among diabetic women on statins—particularly non-Latina Black women—suggesting a possible synergistic protective effect in metabolically vulnerable populations. Yet, only 35% of patients with hypercholesterolemia were prescribed statins. Conclusions/Impact: Statin use was associated with substantially lower HSIL risk, particularly among patients with diabetes. These findings support further investigation of statins as a potential low-cost chemopreventive tool for cervical dysplasia, especially in populations with metabolic dysfunction. Citation Format: Purvika Gautam, Jinlei Zhao, Chelsea Levi, Shreya Raman, Bianca D. Owens, Jerome F. Strauss III, Katherine Y. Tossas. Potential protective effect of statins against HSIL in women with metabolic comorbidities abstract. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr B137.
Gautam et al. (Thu,) studied this question.